Published in Hepatology on February 01, 2005
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90
Management of recurrent hepatitis C following liver transplantation. Gastroenterol Hepatol (N Y) (2010) 0.89
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci (2010) 0.88
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87
Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int (2007) 0.84
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Viruses (2015) 0.82
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? World J Gastroenterol (2014) 0.81
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81
Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol (2014) 0.80
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol (2014) 0.80
Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation. World J Gastroenterol (2007) 0.79
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci (2009) 0.78
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. World J Gastroenterol (2015) 0.77
Management of HCV infection and liver transplantation. Int J Med Sci (2006) 0.77
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. Wien Klin Wochenschr (2006) 0.76
Antiviral treatment of recurrent hepatitis C after liver transplantation: the need for a multifaceted approach. Hepatology (2005) 0.76
Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol (2015) 0.76
Recent advances in liver transplantation for the practicing gastroenterologist. Gastroenterol Hepatol (N Y) (2009) 0.76
Antiviral treatment for hepatitis C virus infection after liver transplantation. Hepat Res Treat (2010) 0.76
Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl (2016) 0.76
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol (2016) 0.75
Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. Am J Case Rep (2016) 0.75
Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol (2016) 0.75
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol (2016) 0.75
Antihepatitis C virus therapy in liver transplanted patients. Ther Clin Risk Manag (2006) 0.75
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol (2015) 0.75
Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study. Ann Surg Treat Res (2015) 0.75
Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. J Korean Med Sci (2015) 0.75
Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepat Res Treat (2016) 0.75
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World J Gastroenterol (2015) 0.75
Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther (2012) 0.75
Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis. Gastroenterol Res Pract (2015) 0.75
Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res (2015) 0.75
Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci (2013) 0.75
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 4.62
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Differentiation of the major Listeria monocytogenes serovars by multiplex PCR. J Clin Microbiol (2004) 4.32
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Wound healing recapitulates morphogenesis in Drosophila embryos. Nat Cell Biol (2002) 4.04
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl (2002) 3.44
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90
Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol (2010) 2.82
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med (2005) 2.68
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
The role of social scientists in synthetic biology. Science & Society Series on Convergence Research. EMBO Rep (2009) 2.57
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology (2003) 2.54
Wound repair at a glance. J Cell Sci (2009) 2.53
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Live imaging of wound inflammation in Drosophila embryos reveals key roles for small GTPases during in vivo cell migration. J Cell Biol (2005) 2.38
New aspects regarding evolution and virulence of Listeria monocytogenes revealed by comparative genomics and DNA arrays. Infect Immun (2004) 2.31
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist (2009) 2.23
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol (2014) 2.17
Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09
Dynamic analysis of dorsal closure in Drosophila: from genetics to cell biology. Dev Cell (2002) 2.06
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl (2003) 2.04
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol (2013) 2.04
Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol (2014) 2.03
Dynamic analysis of filopodial interactions during the zippering phase of Drosophila dorsal closure. Development (2008) 2.03
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2007) 2.00
Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med (2008) 1.99
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci (2004) 1.94
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
Echinococcosis of the liver. Abdom Imaging (2008) 1.88
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.85
Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther (2010) 1.85
The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol (2007) 1.85
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology (2010) 1.80
Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂. Curr Biol (2012) 1.80
Imaging macrophage chemotaxis in vivo: studies of microtubule function in zebrafish wound inflammation. Cell Motil Cytoskeleton (2006) 1.79
Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology (2013) 1.77
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (2012) 1.76
Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol (2005) 1.76
The pharmaceuticalisation of society? A framework for analysis. Sociol Health Illn (2011) 1.75
Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis (2010) 1.75
Molecular caving. Curr Biol (2003) 1.73
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73